How it works
Get started by filling out the online enrollment application to find out if you are eligible for assistance.
NiceRx verifies your eligibility for medication assistance and notifies you if you are pre-qualified. The pharmaceutical company provides your medication for free, and you only pay our service fee.
We will request documents to be submitted by you and your healthcare provider that are required by the pharmaceutical company to complete your enrollment.
Once approved, the pharmaceutical company typically ships a 90-day supply of medication to your home or healthcare provider’s address. Final acceptance is determined by the pharmaceutical company.
Your monthly Enspryng cost savings if eligible
If you are eligible to receive your Enspryng prescription through the patient assistance program, your medication will be free. We charge a flat monthly service fee of $49 per medication to cover the cost of our services.
Am I eligible for Enspryng patient assistance?
To be eligible for the Enspryng patient assistance program, you will need to meet specific eligibility criteria set by the pharmaceutical company. At NiceRx, we review each Enspryng enrollment application individually. The main factors considered are:
- I am a permanent, legal resident of the United States or Puerto Rico
- I am uninsured or my insurance doesn’t cover my medication
- I meet certain income eligibility requirements
How do I apply for the Enspryng patient assistance program?
Applying for the Enspryng patient assistance program through NiceRx is simple. Begin by completing the enrollment application on our website. We will ask for details about your healthcare provider, your insurance plan, and your household income. This information is required by the pharmaceutical manufacturers that supply your medication. We may be able to help you access patient assistance for other medications as well as Enspryng, so please tell us about any medications that you have been prescribed.
If we determine that you may be eligible for Enspryng assistance, we will handle the full enrollment process on your behalf. We will work with your healthcare provider to prepare and submit all the documents required for you to enroll. If you are successfully enrolled in the Enspryng patient assistance program, we will also request your Enspryng medication refills on your behalf for up to 1 year. At the end of your enrollment period, we will contact you for updated details and seek to re-enroll you in the program.
Is NiceRx an Enspryng coupons provider?
NiceRx does not provide Enspryng coupons, discount cards, or copay cards. We do not offer printable Enspryng manufacturer coupons, Enspryng discounts, rebates, Enspryng savings cards, trial offers, or free samples. We are a service provider that helps eligible individuals access patient assistance programs. Our service cost is $49 a month per medication, so you will likely save more on your Enspryng medication with NiceRx.
Can NiceRx help me get Enspryng if I have insurance?
NiceRx may be able to help you access Enspryng patient assistance if:
- You have a high copay or coinsurance responsibility for Enspryng
- Your insurance company will not pay for your Enspryng prescription
- You do not have insurance
Complete your enrollment application online to find out more.
How much does Enspryng cost without insurance?
Enspryng prices without insurance will vary by retailer. As a guide, Enspryng subcutaneous solution (120 mg/mL) will typically cost around $15,300 for 1 milliliter.
How much does Enspryng cost with insurance?
Your individual healthcare plan will determine the copay of Enspryng with insurance. To find out what you will need to pay, contact your pharmacist or insurance provider. They will be able to calculate your copay with your current insurance.
What is Enspryng?
Enspryng is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Genentech, Inc. A Member of the Roche Group.
Enspryng is a humanized monoclonal antibody that is an interleukin-6 (IL-6) receptor antagonist, indicated as a monotherapy or in combination with immunosuppressive therapy for the treatment of NMOSD (neuromyelitis optica spectrum disorder) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.
NMOSD is a rare inflammatory disease of the central nervous system with unpredictable relapses that may lead to cumulative and permanent damage of the optic nerves, spinal cord, and/or brain.
What doses of Enspryng are available?
Enspryng is available in injection form, in the following doses: 120 mg/mL in a single-dose prefilled syringe.
Hepatitis B virus, tuberculosis, and liver transaminase screenings are required before the first dose. The recommended loading dosage for the first three administrations is 120 mg by subcutaneous injection at weeks 0, 2, and 4, then a maintenance dosage of 120 mg every 4 weeks.
For additional safety information, please see the full prescribing information and medication guide. Always speak with your healthcare provider about any changes to your dose so they can monitor and evaluate your condition.
Enspryng active ingredients
Enspryng contains the active ingredient satralizumab-mwge.
Enspryng side effects
The most common side effects of Enspryng in clinical trials include:
- Upper respiratory tract infection
- Arthralgia (joint pain)
- Extremity pain
In rare instances, Enspryng can cause more serious adverse effects. These can include:
- Elevated liver enzymes – monitor ALT and AST levels during treatment
- Decreased neutrophil counts
Discontinue treatment and get emergency medical help if you have signs of an allergic reaction to Enspryng – hives, feeling faint, stomach pain, vomiting, problems breathing, swelling of your face, lips, tongue, or throat.
A healthcare professional will assess the benefits of using Enspryng against your risk of side effects. Patients are encouraged to report negative side effects or adverse reactions of Enspryng to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Enspryng drug interactions
Currently, there is no data for drug interactions with other medicines. Talk to your caregivers about all the medicines you take, including prescription drugs and over-the-counter medicines, vitamins, and herbal supplements.
You should not use Enspryng if you:
- Have had allergic reactions to the active ingredient satralizumab-mwge
- Are allergic to any of the other ingredients in Enspryng
Talk to your doctor before using Enspryng if you:
- Are taking any of the medications that could interact with Enspryng
- Are pregnant or are planning to become pregnant
- Are breastfeeding or are planning to breastfeed
- Have previously had or have an active Hepatitis B infection – HBV reactivation has been observed with other immunosuppressant therapies
- Have active or untreated latent tuberculosis – delay treatment until infection is resolved
- Have recently had a vaccination – using live vaccines is not recommended during treatment
Enspryng is the trademark brand name for satralizumab-mwge manufactured by Genentech, Inc. A Member of the Roche Group. A generic version of satralizumab-mwge is not available. Generic drugs are generally cheaper than brand-name drugs, but you can still find Enspryng savings through NiceRx.
The content on this website is intended for information purposes only. It does not constitute medical advice. The information on this website should not be relied upon and is not a substitute for professional medical advice. You should always speak to your doctor regarding the risks and benefits of any treatment.